IRIS
Pizzato, Massimo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.880
AS - Asia 1.085
EU - Europa 984
SA - Sud America 280
AF - Africa 27
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 1
Totale 6.260
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.850
SG - Singapore 578
IT - Italia 271
CN - Cina 267
BR - Brasile 232
RU - Federazione Russa 181
UA - Ucraina 97
VN - Vietnam 89
FI - Finlandia 77
DE - Germania 74
GB - Regno Unito 63
LV - Lettonia 59
SE - Svezia 50
NL - Olanda 28
ID - Indonesia 26
IN - India 25
AR - Argentina 22
AT - Austria 17
HK - Hong Kong 17
TR - Turchia 17
CA - Canada 15
BD - Bangladesh 14
FR - Francia 13
EC - Ecuador 10
PL - Polonia 10
MX - Messico 9
JP - Giappone 8
IQ - Iraq 7
ZA - Sudafrica 7
CL - Cile 6
CZ - Repubblica Ceca 6
JO - Giordania 6
BG - Bulgaria 5
ES - Italia 5
PK - Pakistan 5
UZ - Uzbekistan 5
VE - Venezuela 5
HU - Ungheria 4
LT - Lituania 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
BY - Bielorussia 3
DZ - Algeria 3
EG - Egitto 3
TW - Taiwan 3
AL - Albania 2
CH - Svizzera 2
CO - Colombia 2
CR - Costa Rica 2
EU - Europa 2
GR - Grecia 2
IE - Irlanda 2
IR - Iran 2
JM - Giamaica 2
KE - Kenya 2
KZ - Kazakistan 2
LB - Libano 2
MA - Marocco 2
NO - Norvegia 2
NP - Nepal 2
PH - Filippine 2
SI - Slovenia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AU - Australia 1
AZ - Azerbaigian 1
BE - Belgio 1
BO - Bolivia 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
GM - Gambi 1
HN - Honduras 1
IL - Israele 1
KR - Corea 1
MK - Macedonia 1
MU - Mauritius 1
MY - Malesia 1
NG - Nigeria 1
PS - Palestinian Territory 1
PY - Paraguay 1
RS - Serbia 1
RW - Ruanda 1
SK - Slovacchia (Repubblica Slovacca) 1
TZ - Tanzania 1
UY - Uruguay 1
YT - Mayotte 1
Totale 6.260
Salva come PNG Salva come JPEG
Città #
Fairfield 508
Ashburn 423
Singapore 378
Chandler 281
Woodbridge 249
Seattle 226
Jacksonville 220
Wilmington 192
Cambridge 176
Houston 164
Dallas 129
Santa Clara 129
Columbus 103
Ann Arbor 96
Moscow 86
Trento 85
Princeton 84
San Mateo 81
Riga 59
New York 58
Beijing 57
Los Angeles 53
Munich 38
Boardman 31
Helsinki 27
Ho Chi Minh City 27
Como 26
Chicago 25
San Diego 25
Rome 22
São Paulo 22
Jakarta 21
Dearborn 20
London 19
Buffalo 18
The Dalles 18
Council Bluffs 16
Hanoi 16
Hefei 16
Hong Kong 16
Redondo Beach 15
Dong Ket 12
Milan 11
Chennai 10
Vienna 10
Warsaw 10
Lappeenranta 9
San Paolo di Civitate 9
Verona 9
Guangzhou 8
Orem 8
Poplar 8
Tokyo 8
Falkenstein 7
Izmir 7
Montreal 7
Turku 7
Amsterdam 6
Denver 6
Elk Grove Village 6
Jinan 6
Johannesburg 6
Nuremberg 6
Turin 6
Washington 6
Belo Horizonte 5
Brasília 5
Bremen 5
Fort Worth 5
Frankfurt am Main 5
Fremont 5
Mexico City 5
Mumbai 5
Phoenix 5
Quito 5
Salt Lake City 5
Sofia 5
Tashkent 5
Toronto 5
Brno 4
Brooklyn 4
Brugherio 4
Düsseldorf 4
Miami 4
Rio de Janeiro 4
Riva Del Garda 4
San Francisco 4
Shenzhen 4
Volargne 4
Atlanta 3
Boston 3
Budapest 3
Buenos Aires 3
Changsha 3
Dedham 3
Hangzhou 3
Irvine 3
Islington 3
João Pessoa 3
Kilburn 3
Totale 4.586
Salva come PNG Salva come JPEG
Nome #
SERINC5 as a new restriction factor for human immunodeficiency virus and murine leukemia virus 188
A bipartite structural organization defines the SERINC family of HIV-1 restriction factors 178
SARS-CoV-2 and the Host Cell: A Tale of Interactions 174
A Community Study of SARS-CoV-2 Detection by RT-PCR in Saliva: A Reliable and Effective Method 170
SERINC5 protein inhibits HIV-1 fusion pore formation by promoting functional inactivation of envelope glycoproteins 169
HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation 162
The antiviral activity of rodent and lagomorph SERINC3 and SERINC5 is counteracted by known viral antagonists 154
Retroviral factors promoting infectivity. 152
Serology study after BTN162b2 vaccination in participants previously infected with SARS-CoV-2 in two different waves versus naïve 149
The antagonism of HIV Nef to SERINC5 particle infectivity restriction involves the counteraction of virion-associated pools of the restriction factor 148
Galanin pathogenic mutations in temporal lobe epilepsy 146
Evidence for nonspecific adsorption of targeted retrovirus vector particles to cells. 144
The Potency of Nef-Mediated SERINC5 Antagonism Correlates with the Prevalence of Primate Lentiviruses in the Wild 143
Lv4 Is a Capsid-Specific Antiviral Activity in Human Blood Cells That Restricts Viruses of the SIVMAC/SIVSM/HIV-2 Lineage Prior to Integration 141
S2 from equine infectious anemia virus is an infectivity factor which counteracts the retroviral inhibitors SERINC5 and SERINC3 140
Gene Therapy of Glioblastoma Multiforme with a Bicistronic Retroviral Vector Expressing Human IL-2 and HSV-tK. 139
The host-cell restriction factor SERINC5 restricts HIV-1 infectivity without altering the lipid composition and organization of viral particles 139
Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. 137
Effect of High-Energy Milling on the Dissolution of Anti-HIV Drug Efavirenz in Different Solvents 134
Mechanical activation of Efavirenz: the effects on the dissolution and inhibitory behavior 130
Centriolar distal appendages activate the centrosome-PIDDosome-p53 signalling axis via ANKRD26 127
Dynamin 2 is required for the enhancement of HIV-1 infectivity by Nef. 125
Sterile inflammation via TRPM8 RNA-dependent TLR3-NF-kB/IRF3 activation promotes antitumor immunity in prostate cancer 120
Effect of differential growth conditions on the dTTP pool size in herpes simplex virus-infected Vero cells. 116
TRIM5 is an innate immune sensor for the retrovirus capsid lattice. 115
Insertion of targeting domains into the envelope glycoprotein of Moloney murine leukemia virus (MoMLV)-based vectors modulates the route of mCAT-1-mediated viral entry. 112
A one-step SYBR Green I-based product-enhanced reverse transcriptase assay for the quantitation of retroviruses in cell culture supernatants. 111
Cyclosporine blocks incorporation of HIV-1 envelope glycoprotein into virions. 109
Development of a suspension packaging cell line for production of high titre, serum-resistant murine leukemia virus vectors. 108
Progress with retroviral gene vectors. 107
Nef can enhance the infectivity of receptor-pseudotyped human immunodeficiency virus type 1 particles. 106
Quantification of reverse transcriptase activity by real-time PCR as a fast and accurate method for titration of HIV, lenti- and retroviral vectors. 102
Molecular cloning, complete sequence, and biological characterization of a xenotropic murine leukemia virus constitutively released from the human B-lymphoblastoid cell line DG-75. 100
Heparin binds to murine leukemia virus and inhibits Env-independent attachment and infection. 99
Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research. 98
Nef enhances human immunodeficiency virus type 1 infectivity in the absence of matrix. 97
The carboxyl-terminus of human immunodeficiency virus type 2 circulating recombinant form 01_AB capsid protein affects sensitivity to human TRIM5α. 97
Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41. 96
Determination of HPRT mutant frequency and molecular analysis of T-lymphocyte mutants derived from coke-oven workers. 94
Production and characterization of a bicistronic Moloney-based retroviral vector expressing human interleukin 2 and herpes simplex virus thymidine kinase for gene therapy of cancer. 93
MLV glycosylated-Gag is an infectivity factor that rescues Nef-deficient HIV-1. 93
Viral particles imaging through evanescent wave scattering in a total internal reflection laser microscope 92
Localization to detergent-resistant membranes and HIV-1 core entry inhibition correlate with HIV-1 restriction by SERINC5 92
Herpes simplex virus chronically infected human T lymphocytes are susceptible to HIV-1 superinfection and support HIV-1 pseudotyping. 83
Immunogenicity and Pre-Clinical Efficacy of an OMV-Based SARS-CoV-2 Vaccine 81
The activity of Nef on HIV-1 infectivity. 81
SARS-CoV-2 vaccination elicits unconventional IgM specific responses in naïve and previously COVID-19-infected individuals 77
SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity 77
Doxycycline Inhibition of a Pseudotyped Virus Transduction Does Not Translate to Inhibition of SARS-CoV-2 Infectivity 69
Initial binding of murine leukemia virus particles to cells does not require specific Env-receptor interaction. 65
Host Restriction Factors Modulating HIV Latency and Replication in Macrophages 64
Retrovirus vectors. 62
The impact of infection risk communication format on tourism travel intentions during COVID-19 58
A Conserved Acidic Residue in the C-Terminal Flexible Loop of HIV-1 Nef Contributes to the Activity of SERINC5 and CD4 Downregulation 56
Impaired ability of Nef to counteract SERINC5 is associated with reduced plasma viremia in HIV-infected individuals 51
Prospective epidemiological, molecular, and genetic characterization of a novel coronavirus disease in the Val Venosta/Vinschgau: the CHRIS COVID-19 study protocol 51
Trends and symptoms of SARS-CoV-2 infection: a longitudinal study on an Alpine population representative sample 48
Influence of Different Glycoproteins and of the Virion Core on SERINC5 Antiviral Activity 43
Totale 6.412
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.134
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 448
Totale 28.582
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021420 0 0 0 0 0 44 48 56 46 74 99 53
2021/2022481 22 32 8 20 12 31 7 106 48 49 59 87
2022/2023607 63 68 6 69 52 87 9 54 113 35 31 20
2023/2024332 20 20 18 20 34 84 21 22 5 13 12 63
2024/20251.332 17 11 75 247 79 166 115 82 137 234 76 93
2025/20261.448 184 82 330 476 362 14 0 0 0 0 0 0
Totale 6.412